{"entity":{"type":"insider","cik":"0001725595","url":"/insider/0001725595","json_url":"/insider/0001725595.json","name":"LEWIS JOEL","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":15,"first":"2018-06-26","last":"2026-01-06","span_basis":"filed_date"},"name_variants":[{"name":"LEWIS JOEL","source":"filing","n_filings":15,"first_seen":"2018-06-26","last_seen":"2026-01-06"}],"transactions":[{"id":5821519,"accession":"0001133416-26-000008","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001133416-26-000008","line_url":"/filing/0001133416-26-000008#line-4","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37698.0,"shares_display":"37,698","price_per_share":3.5772,"price_display":"3.58","price_state":"stated","total_value":134853.2856,"total_display":"134,853.29","total_whole":"134,853","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-06","filed_date":"2026-01-06","scope":"insider"},{"id":5821517,"accession":"0001133416-26-000008","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001133416-26-000008","line_url":"/filing/0001133416-26-000008#line-3","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27731.0,"shares_display":"27,731","price_per_share":3.9069,"price_display":"3.91","price_state":"stated","total_value":108342.2439,"total_display":"108,342.24","total_whole":"108,342","shares_owned_after":870290.0,"shares_owned_after_display":"870,290","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-06","scope":"insider"},{"id":5821515,"accession":"0001133416-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-26-000008","line_url":"/filing/0001133416-26-000008#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18571.0,"shares_display":"18,571","price_per_share":4.1968,"price_display":"4.20","price_state":"stated","total_value":77938.7728,"total_display":"77,938.77","total_whole":"77,939","shares_owned_after":898021.0,"shares_owned_after_display":"898,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-06","scope":"insider"},{"id":4031266,"accession":"0001133416-25-000071","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000071","line_url":"/filing/0001133416-25-000071#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7829.0,"shares_display":"7,829","price_per_share":7.056,"price_display":"7.06","price_state":"stated","total_value":55241.424,"total_display":"55,241.42","total_whole":"55,241","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-17","filed_date":"2025-12-19","scope":"insider"},{"id":4878386,"accession":"0001133416-25-000058","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001133416-25-000058","line_url":"/filing/0001133416-25-000058#line-4","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6783.0,"shares_display":"6,783","price_per_share":6.1511,"price_display":"6.15","price_state":"stated","total_value":41722.9113,"total_display":"41,722.91","total_whole":"41,723","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-19","scope":"insider"},{"id":4878377,"accession":"0001133416-25-000058","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000058","line_url":"/filing/0001133416-25-000058#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15680.0,"shares_display":"15,680","price_per_share":6.0359,"price_display":"6.04","price_state":"stated","total_value":94642.912,"total_display":"94,642.91","total_whole":"94,643","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-17","filed_date":"2025-11-19","scope":"insider"},{"id":5024111,"accession":"0001133416-25-000052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000052","line_url":"/filing/0001133416-25-000052#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1867.0,"shares_display":"1,867","price_per_share":6.0269,"price_display":"6.03","price_state":"stated","total_value":11252.2223,"total_display":"11,252.22","total_whole":"11,252","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-10","filed_date":"2025-11-12","scope":"insider"},{"id":4455205,"accession":"0001133416-25-000048","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000048","line_url":"/filing/0001133416-25-000048#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":1200.0,"total_display":"1,200.00","total_whole":"1,200","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-05","filed_date":"2025-11-07","scope":"insider"},{"id":4424680,"accession":"0001133416-25-000044","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001133416-25-000044","line_url":"/filing/0001133416-25-000044#line-4","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14420.0,"shares_display":"14,420","price_per_share":6.07,"price_display":"6.07","price_state":"stated","total_value":87529.4,"total_display":"87,529.40","total_whole":"87,529","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-04","filed_date":"2025-11-05","scope":"insider"},{"id":4424672,"accession":"0001133416-25-000044","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000044","line_url":"/filing/0001133416-25-000044#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":6.01,"price_display":"6.01","price_state":"stated","total_value":7813.0,"total_display":"7,813.00","total_whole":"7,813","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-05","scope":"insider"},{"id":4753773,"accession":"0001133416-25-000038","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-25-000038","line_url":"/filing/0001133416-25-000038#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14000.0,"shares_display":"14,000","price_per_share":6.3606,"price_display":"6.36","price_state":"stated","total_value":89048.4,"total_display":"89,048.40","total_whole":"89,048","shares_owned_after":832592.0,"shares_owned_after_display":"832,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-12","filed_date":"2025-09-15","scope":"insider"},{"id":3204291,"accession":"0001133416-24-000070","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001133416-24-000070","line_url":"/filing/0001133416-24-000070#line-2","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56000.0,"shares_display":"56,000","price_per_share":0.8859,"price_display":"0.89","price_state":"stated","total_value":49610.4,"total_display":"49,610.40","total_whole":"49,610","shares_owned_after":897012.0,"shares_owned_after_display":"897,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-26","scope":"insider"},{"id":2242339,"accession":"0001133416-24-000040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001133416-24-000040","line_url":"/filing/0001133416-24-000040#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":3.39,"price_display":"3.39","price_state":"stated","total_value":3390.0,"total_display":"3,390.00","total_whole":"3,390","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-24","filed_date":"2024-04-25","scope":"insider"},{"id":8361150,"accession":"0001133416-23-000041","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001133416-23-000041","line_url":"/filing/0001133416-23-000041#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":1520.0,"total_display":"1,520.00","total_whole":"1,520","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-16","filed_date":"2023-02-21","scope":"insider"},{"id":7845294,"accession":"0001179022-19-000033","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179022-19-000033","line_url":"/filing/0001179022-19-000033#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12849.0,"shares_display":"12,849","price_per_share":4.28,"price_display":"4.28","price_state":"stated","total_value":54993.72,"total_display":"54,993.72","total_whole":"54,994","shares_owned_after":78649.0,"shares_owned_after_display":"78,649","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-31","filed_date":"2019-06-03","scope":"insider"},{"id":8565725,"accession":"0001179022-19-000030","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179022-19-000030","line_url":"/filing/0001179022-19-000030#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":667.0,"shares_display":"667","price_per_share":4.8187,"price_display":"4.82","price_state":"stated","total_value":3214.0729,"total_display":"3,214.07","total_whole":"3,214","shares_owned_after":65800.0,"shares_owned_after_display":"65,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-05","filed_date":"2019-04-08","scope":"insider"},{"id":7918632,"accession":"0001179022-19-000026","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179022-19-000026","line_url":"/filing/0001179022-19-000026#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":4.4841,"price_display":"4.48","price_state":"stated","total_value":4484.1,"total_display":"4,484.10","total_whole":"4,484","shares_owned_after":65133.0,"shares_owned_after_display":"65,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-07","filed_date":"2019-02-11","scope":"insider"},{"id":8038738,"accession":"0001179022-19-000022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179022-19-000022","line_url":"/filing/0001179022-19-000022#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":4.805,"price_display":"4.80","price_state":"stated","total_value":4805.0,"total_display":"4,805.00","total_whole":"4,805","shares_owned_after":64133.0,"shares_owned_after_display":"64,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-29","filed_date":"2019-01-30","scope":"insider"},{"id":6490347,"accession":"0001179022-18-000057","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179022-18-000057","line_url":"/filing/0001179022-18-000057#line-1","is_derivative":false,"issuer_cik":"0001133416","issuer_name":"GALECTIN THERAPEUTICS INC","issuer_ticker":"GALT","issuer_name_source":null,"issuer_url":"/issuer/0001133416","owner_cik":"0001725595","owner_name":"LEWIS JOEL","owner_display_name":"LEWIS JOEL","owner_url":"/insider/0001725595","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":7.0584,"price_display":"7.06","price_state":"stated","total_value":7058.4,"total_display":"7,058.40","total_whole":"7,058","shares_owned_after":51480.0,"shares_owned_after_display":"51,480","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":7,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001133416","name":"GALECTIN THERAPEUTICS INC","url":"/issuer/0001133416","role":"Director, Officer (President and CEO)","n_filings":15,"first_seen":"2018-06-26","last_seen":"2026-01-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001725595","retrieved_at":"2026-08-22T20:54:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}